Alice Tsang Shaw, MD, PhD, is a thoracic oncologist at the Massachusetts General Hospital Cancer Center.




Centers & Specialties

Cancer Center

Clinical Interests
  • Lung cancer treatment
Medical Education
  • MD, Harvard Medical School
  • PhD, Harvard University
  • Residency, Massachusetts General Hospital
  • Fellowship, Dana Farber Cancer Institute
Board Certifications
  • Medical Oncology
  • Boston: Massachusetts General Hospital
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • Cigna (PAL #'s)
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • MassHealth
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • Private Health Care Systems (PHCS)
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.

Patient Age Group

Edit Profile


Alice T. Shaw, MD, PhD, is an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital and an associate professor of medicine at Harvard Medical School.  In addition to caring for patients with lung cancer, Dr. Shaw also performs clinical and translational research.

Dr. Shaw's major research interests include studying anaplastic lymphoma kinase (ALK) and ROS1 rearrangements in non-small cell lung carcinoma (NSCLC).  She is also studying how lung cancers develop resistance to targeted therapies, and this work has led to a number of novel treatment strategies to overcome resistance in the clinic.  Dr Shaw has been awarded a number of research grants, including grants from the Damon Runyon Cancer Research Foundation, the Burroughs Welcome Fund, the V Foundation for Cancer Research, Uniting Against Lung Cancer, the National Foundation for Cancer Research, and the NIH/NCI.

Edit Profile

News & Events

  • Cancer patient wins dream wedding

    Justin Perry from Wells, Maine looks like a typical 25-year-old man. At a recent appointment at the MGH Cancer Center, flanked by his supportive parents and loving fiancée, Michelle White, he doesn’t look like he is fighting a diagnosis of stage 4 lung cancer.

  • Athlete with lung cancer finds needed care at the MGH

    Two years ago, Yariv “Dolio” Kafri was an active, committed 47-year-old athlete. A one-time member of the Israeli national volleyball team, he had played soccer for many years, and was a surfer, triathlete, yogi and biker. He was in excellent physical condition and had never smoked a day in his life.

  • Personalizing cancer therapies may combat resistance to targeted therapy drugs

    In a study examining the evolution of drug resistance in a lung cancer patient treated with multiple different targeted therapies, MGH physicians report that a new mutation conferring resistance to a next-generation targeted therapy actually restored the cancer’s response to the very first targeted therapy drug used to treat the patient.

  • Crizotinib treatment effective against ROS1-positive lung cancer

    Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene

  • New drug successfully treats crizotinib-resistant, ALK-positive lung cancer

    A new drug called ceritinib appears to be effective against advanced ALK-positive non-small cell lung cancer, both in tumors that have become resistant to crizotinib and in those never treated with the older drug.

  • MGH-led studies shed new light on targeted lung cancer therapy

    Research teams led by Massachusetts General Hospital (MGH) Cancer Center investigators are publishing two important studies regarding use of the targeted cancer drug crizotinib for treatment of advanced lung cancer driven by specific genetic mutations.

  • Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer

    The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer.

  • Mass. General study defines a new genetic subtype of lung cancer

    MGH Cancer Center investigators have defined the role of a recently identified gene abnormality – rearrangements in the ROS1 gene – in non-small-cell lung cancer, the leading cause of cancer death in the U.S. They also show that these tumors can be treated with crizotinib and describe the remarkable response of one patient to such treatment.


  • Alice Shaw, MD, explains why patients with lung cancer can benefit from genetic testing

    Alice Shaw, MD, thoracic oncologist at the Mass General Cancer Center, says patients with lung cancer can benefit from genetic testing, particularly if they are young non-smokers. Learn more about personalized treatment for lung cancer and new "smart drugs" that target a tumor's specific genetic mutation to slow the cancer's growth, and in some cases, reduce it significantly.


55 Fruit Street
Boston, MA 02114-2696
Phone: 617-724-4000
Fax: 617-726-0453

Edit Profile